NMTRQ (9 Meters Biopharma) General and Admin. Expense: $11.00 Mil (TTM As of Mar. 2023)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is 9 Meters Biopharma General and Admin. Expense?

9 Meters Biopharma NMTRQ -90.00% General and Admin. Expense is $11.00 Mil as of Mar. 2023.

General and Admin. Expense is the aggregate total of general managing and administering expenses for the company. 9 Meters Biopharma's General and Admin. Expense for the three months ended in Mar. 2023 was $2.99 Mil. Its General and Admin. Expense for the trailing twelve months (TTM) ended in Mar. 2023 was $11.00 Mil.

9 Meters Biopharma General and Admin. Expense Related Terms

9 Meters Biopharma General and Admin. Expense Historical Data

* Premium members only.

The historical data trend for 9 Meters Biopharma's General and Admin. Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

9 Meters Biopharma General and Admin. Expense Chart

9 Meters Biopharma Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
General and Admin. Expense
Get a 7-Day Free Trial Premium Member Only Premium Member Only 10.67 10.57 10.52 9.66 11.01

9 Meters Biopharma Quarterly Data
Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23
General and Admin. Expense Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 3.00 3.65 2.42 1.95 2.99

9 Meters Biopharma General and Admin. Expense Calculation

General and Admin. Expense is the aggregate total of general managing and administering expenses for the company.

General and Admin. Expense for the trailing twelve months (TTM) ended in Mar. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $11.00 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a General and Admin. Expense of $11.00 Mil mean?
9 Meters Biopharma (NMTRQ) has a General and Admin. Expense of $11.00 Mil as of Mar. 2023. General and Admin. Expense is the aggregate total of general managing and administering expenses for the company. View historical data on 9 Meters Biopharma and its competitors.
Is 9 Meters Biopharma's General and Admin. Expense too high?
9 Meters Biopharma's current General and Admin. Expense is $11.00 Mil.
How does 9 Meters Biopharma's General and Admin. Expense compare to USRM and NOVNQ?
9 Meters Biopharma's General and Admin. Expense of $11.00 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good General and Admin. Expense for a Biotechnology company?
A good General and Admin. Expense depends on the Biotechnology industry context. However, General and Admin. Expense should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high General and Admin. Expense mean?
A high General and Admin. Expense can signal that a stock is expensive relative to its fundamentals. General and Admin. Expense is the aggregate total of general managing and administering expenses for the company. View historical data on 9 Meters Biopharma and its competitors. 9 Meters Biopharma's current General and Admin. Expense is $11.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is 9 Meters Biopharma stock overvalued right now?
9 Meters Biopharma (NMTRQ) has a current General and Admin. Expense of $11.00 Mil. The current General and Admin. Expense is $11.00 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is General and Admin. Expense calculated?
General and Admin. Expense is calculated from a company's financial statements. For 9 Meters Biopharma (NMTRQ), the current General and Admin. Expense is $11.00 Mil as of Mar. 2023. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

9 Meters Biopharma Business Description

Address 4509 Creedmoor Road, Suite 600, Raleigh, NC, USA, 27612
9 Meters Biopharma Inc is a clinical-stage company pioneering novel treatments for people with rare digestive diseases, gastrointestinal (GI) conditions with unmet needs, and debilitating disorders in which the biology of the gut is a contributing factor. Its pipeline includes vurolenatide, a proprietary Phase 3 long-acting glucagon-like-peptide 1 (GLP-1) agonist for short bowel syndrome (SBS) and a robust pipeline of early-stage candidates for undisclosed rare diseases and/or unmet needs.